Sole control: The French Competition Authority clears a group active in the medical biology sector to take sole control of a company provided that it renounces to acquire a minority stake in the only competitor of the target on the market of routine medical biology tests (Bio Pôle Antilles / Inovie)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. In the last few days, the French Competition Authority has posted 29 new merger clearance decisions online, including 26 simplified decisions. Among these decisions is decision n° 22-DCC-35 of April 27, 2022 in which the French Competition Authority authorized the Inovie group, which operates more than 400 medical laboratories located mainly in the southern half of France, in the Île-de-France region and on Reunion Island, to acquire sole control of Bio Pôle Antilles, which operates 14 medical laboratories, including 11 in Guadeloupe, two in Saint-Martin and one in Saint-Barthélémy. However, this authorization was only granted on condition that the Inovie

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Sole control: The French Competition Authority clears a group active in the medical biology sector to take sole control of a company provided that it renounces to acquire a minority stake in the only competitor of the target on the market of routine medical biology tests (Bio Pôle Antilles / Inovie), 27 April 2022, Concurrences N° 2-2022, Art. N° 106978, www.concurrences.com

Visites 54

All reviews